Moderna Posts 38-Cent Q3 EPS, Swinging to Profit
MRNA has more than doubled off its 52-week low of $22.28.
Summary
Moderna reported third-quarter earnings per share of 38 cents, a swing to profitability after the company posted a $782 million net loss in the second quarter, on revenue of $1.31 billion. The result lands after a transformative stretch: the intismeran melanoma vaccine data in August sent shares up 177% in a single session, and the company raised $3.0 billion in convertible notes at a 47.5% conversion premium in early September. A profitable quarter supports the case that the cancer vaccine franchise and the newly approved flu and COVID products can carry the P&L while the core COVID business normalizes. Guidance and the margin bridge are not yet in hand.
At the time of this announcement, MRNA was trading at $237.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $96.4B. The 52-week trading range was $22.28 to $261.00. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.